riskScore can provide personalized a risk assessment for certain women for both a 5-year and remaining lifetime risk by looking at several personalized factors​.

Myriad myRisk Enhanced With riskScore

myrisk + Cancer History Analysis = RiskScore Precision Medicine

In addition to offering accurate hereditary cancer test results, Myriad myRisk® includes riskScore for eligible women to provide more comprehensive breast cancer risk assessment.

What Is riskScore?

riskScore provides comprehensive, personalized risk assessment for certain women for a 5-year and remaining lifetime risk of developing breast cancer, analyzing several personalized factors at no additional cost. 

riskScore can provide further insight for certain women who remain high-risk without a pathogenic mutation. By incorporating over 80 well-studied and validated genetic markers with the Tyrer-Cuzick risk model, riskScore reports a 5-year and remaining lifetime risk for breast cancer. Women who receive a riskScore will have this information included in the myRisk Management Tool to assist in the development of a treatment plan.

To see who is eligible for riskScore, click here

riskScore Now Offers More Clarity For A Woman’s Risk Of Breast Cancer

Women without a gene mutation Women with a CHEK2 Mutation

Personalized Breast Cancer Risk Assessment For Women Without A Pathogenic Mutation

This means that certain patients will receive more critical information to help guide your medical management plan for breast cancer prevention and early identification.

Breast Cancer Unaffected Risk Score Example

Personalized Breast Cancer Risk For CHEK2 Mutation Carriers

Recommend a medical management plan based on the a woman’s personal risk of breast cancer instead of a range of risk assoiciated with a pathogenic CHEK2 mutation.

Breast Cancer CHEK2 Risk Score Example



riskScore has been validated in multiple studies and continues to advance the science of breast cancer risk assessment. First presented at the American Society of Clinical Oncology Meeting (ASCO) in 2017, the genetic markers used in riskScore have been peer-reviewed and published in JCO Precision Oncology.

In addition to the validation of the genetic markers used in riskScore, Myriad continues to publish studies and advance the science of breast cancer risk assessment. To review all of our published studies, visit our Publications page.

myRisk Management Tool

In addition to myRisk results, the myRisk Management Tool will include riskScore results and leading society guidelines for patients who may be at or above the 20% threshold for consideration of modified medical management. Your patient’s clinical history will also be included in an easy-to-read format to provide you and your patient with as much information as possible as your form a plan together.

Current Eligibility For riskScore

riskScore has been validated based on previously identified genetic markers that are specific to certain populations, cancer histories, and mutation statuses.

  1. Woman under age 85
  2. European and Ashkenazi Jewish ancestry
  3. No personal history of breast cancer, LCIS, hyperplasia, atypical hyperplasia, or a breast biopsy with unknown results
  4. The woman does not have a mutation in a breast cancer gene (excluding monoallelic CHEK2)
  5. The woman’s relatives have not been found to have a mutation in a high-penetrance breast cancer risk gene.*

*High-penetrance breast cancer risk genes: BRCA1, BRCA2, CDH1, PALB2, PTEN, STK11, TP53, ATM c.7271T>G., and bi-allelic CHEK2

Global riskScore

Committed to Making Breast Cancer Risk Assessment Available To Every Woman

Myriad is on the forefront of hereditary cancer testing and breast cancer risk assessment and is working diligently towards expanding accessibility to riskScore for women of all ancestries.

Learn More

Stay Updated On Future Advancements To myRisk Enhanced With riskScore

If you have further questions about riskScore, contact your local Myriad Account Executive or Regional Medical Specialists or call 1-800-4-MYRIAD

Sign up to receive riskScore email udpates

Myriad is committed to protecting and respecting your privacy, and we’ll only use your personal information to administer your account and to provide the products and services you requested from us.

From time to time, we would like to contact you about our products and services, as well as other content that may be of interest to you. If you consent to us contacting you for this purpose, please tick below to say how you would like us to contact you:

You can unsubscribe from these communications at any time. For more information on how to unsubscribe, our privacy practices, and how we are committed to protecting and respecting your privacy, please review our Privacy Policy.

By clicking submit below, you consent to allow Myriad to store and process the personal information submitted above to provide you the content requested.
Hidden Fields


  1. Mavaddat N, et al. Prediction of breast cancer risk based on profiling with common genetic variants. J Natl Cancer Inst. 2015 Apr 8;107(5). PubMed.
  2. Michailidou K, et al. Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nat Genet. 2013 Apr;45(4): 353-61.
  3. Michailidou K, et al. Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer. Nat Genet. 2015 Apr;47(4):373-80. PubMed.
  4. Tyrer J, et al. A breast cancer prediction model incorporating familial and personal risk factors. Stat Med. 2004 23:1111-30.